Cannas Giovanna, Poutrel Solène, Virot Emilie, Marie Manon, Guilhem Alexandre, El-Kanouni Amal, Bourgeay Richard, Mutumwa Marie-Grace, Elhamri Mohamed, Hot Arnaud
Internal Medicine, Hospices Civils de Lyon, Edouard Herriot Hospital, Lyon, France.
Constitutive reference center, Major sickle cell syndromes, thalassemia and other rare pathologies of red blood cell and erythropoiesis, Edouard Herriot Hospital, Lyon. France.
Mediterr J Hematol Infect Dis. 2025 Sep 1;17(1):e2025065. doi: 10.4084/MJHID.2025.065. eCollection 2025.
Sickle cell disease (SCD) is a genetic disease of public health concern. Adult patients face various disease-related complications, which affect their quality of life (QoL). Few studies have examined relationships between these events and health-related (HR) QoL. We conducted a study of 240 adults with SCD seen in steady state at a routine clinic visit over one year. Two self-administered questionnaires were used to determine patients' HRQoL: the sickle cell self-efficacy scale (SCSES) comprising 9 specific items and the unspecific SF-36 scoring system comprising 8 subscales, which construct the physical component summary (PCS) and the mental component summary (MCS). Factors impacting HRQoL were established using univariate and multivariate regression analyses. Participants had a median age of 28 years (Sex ratio male/female 0.61; 68% SS genotype). Most of them had experienced more than one SCD-related complication and more than one affected organ system. A good correlation was established between the SCD-specific and the unspecific scoring systems (p < 0.0001). Using the SF-36 scoring system, energy/fatigue, general health, and pain subscales showed the lowest median scores (50, 45, and 56.5, respectively), while physical functioning had the highest median score (75). In univariate and multivariate analyses, hospitalization for SCD complications occurring during the last year preceding QoL evaluation was the main feature impacting HRQoL (p < 0.001). Good compliance to hydroxyurea (HU) therapy was associated with higher SCSES (p = 0.04) and higher emotional role functioning (p = 0.03) scores. The recent occurrence of severe SCD complications mainly influenced HRQoL. Our study suggests that a more effective treatment through better compliance with HU therapy would provide benefit in terms of QoL.
镰状细胞病(SCD)是一种受到公共卫生关注的遗传性疾病。成年患者面临各种与疾病相关的并发症,这些并发症会影响他们的生活质量(QoL)。很少有研究探讨这些事件与健康相关(HR)生活质量之间的关系。我们对在一年期间于常规门诊就诊时处于稳定状态的240名成年SCD患者进行了一项研究。使用两份自我管理问卷来确定患者的HRQoL:包含9个特定项目的镰状细胞自我效能量表(SCSES)和包含8个分量表的非特定SF-36评分系统,该系统构建了身体成分总结(PCS)和心理成分总结(MCS)。使用单变量和多变量回归分析确定影响HRQoL的因素。参与者的年龄中位数为28岁(男女比例为0.61;68%为SS基因型)。他们中的大多数人经历过不止一种与SCD相关的并发症以及不止一个受影响的器官系统。在SCD特异性评分系统和非特异性评分系统之间建立了良好的相关性(p < 0.0001)。使用SF-36评分系统时,精力/疲劳、总体健康和疼痛分量表的中位数得分最低(分别为50、45和56.5),而身体功能的中位数得分最高(75)。在单变量和多变量分析中,在QoL评估前一年期间因SCD并发症住院是影响HRQoL的主要特征(p < 0.001)。对羟基脲(HU)治疗的良好依从性与较高的SCSES得分(p = 0.04)和较高的情感角色功能得分(p = 0.03)相关。近期发生的严重SCD并发症主要影响HRQoL。我们的研究表明,通过更好地依从HU治疗进行更有效的治疗将在QoL方面带来益处。